腫瘍治療薬の中国市場:化学療法、標的療法、免疫療法、ホルモン療法

Chapter 1: Introduction

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments

1.3.1. List of Key Players Profiled In The Report

1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies, 2018

3.3. Porter’S Five Forces Analysis
3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Industrial Collaboration
3.4.1.2. In House Manufacturing
3.4.1.3. Increase In Incidences of Cancers In The Chinese Population

3.4.2. Restraint

3.4.2.1. Preference of Generics And Biosimilars

3.4.3. Opportunity

3.4.3.1. Increase In Number of Pipeline Drugs

3.4.4. Impact Analyses

Chapter 4: China Oncology Drugs Market, By Drug Class Type

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Chemotherapy

4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast

4.3. Targeted Therapy

4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast

4.4. Immunotherapy (Biologic Therapy)

4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast

4.5. Hormonal Therapy

4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast

Chapter 5: China Oncology Drugs Market, By Indication

5.1. Overview

5.1.1. Cancer Incidences In China, 2018
5.1.2. Market Size And Forecast

5.2. Blood Cancer

5.2.1. Market Size And Forecast

5.3. Breast Cancer

5.3.1. Market Size And Forecast

5.4. Gastrointestinal And Urinary Cancer

5.4.1. Market Size And Forecast
5.4.2. Gb/Cholangiocarcinoma

5.4.2.1. Market Size And Forecast

5.4.3. Bladder Cancer

5.4.3.1. Market Size And Forecast

5.4.4. Pancreatic Cancer

5.4.4.1. Market Size And Forecast

5.5. Prostate Cancer

5.5.1. Market Size And Forecast

5.6. Lung Cancer

5.6.1. Market Size And Forecast
5.6.2. Small Cell Lung Cancer (Sclc)

5.6.2.1. Market Size And Forecast

5.7. Skin Cancer

5.7.1. Market Size And Forecast

5.8. Ovarian Cancer

5.8.1. Market Size And Forecast

5.9. Cervical Cancer

5.9.1. Market Size And Forecast

5.10. Kidney Cancer

5.10.1. Market Size And Forecast,

5.11. Other Cancers

5.11.1. Market Size And Forecast

Chapter 6: Company Profiles

6.1. Abbvie Inc.

6.1.1. Company Overview
6.1.2. Company Snapshot
6.1.3. Operating Business Segments
6.1.4. Product Portfolio
6.1.5. Business Performance

6.2. Astellas Pharma Inc.

6.2.1. Company Overview
6.2.2. Company Snapshot
6.2.3. Operating Business Segments
6.2.4. Product Portfolio
6.2.5. Business Performance

6.3. Astrazeneca Plc

6.3.1. Company Overview
6.3.2. Company Snapshot
6.3.3. Operating Business Segments
6.3.4. Product Portfolio
6.3.5. Business Performance

6.4. Bristol-Myers Squibb Company

6.4.1. Company Overview
6.4.2. Company Snapshot
6.4.3. Operating Business Segments
6.4.4. Product Portfolio
6.4.5. Business Performance
6.4.6. Key Strategic Moves And Developments

6.5. Celgene Corporation

6.5.1. Company Overview
6.5.2. Company Snapshot
6.5.3. Operating Business Segments
6.5.4. Product Portfolio
6.5.5. Business Performance
6.5.6. Key Strategic Moves And Developments

6.6. F. Hoffmann-La Roche Ltd.

6.6.1. Company Overview
6.6.2. Company Snapshot
6.6.3. Operating Business Segments
6.6.4. Product Portfolio
6.6.5. Business Performance
6.6.6. Key Strategic Moves And Developments

6.7. Johnson & Johnson

6.7.1. Company Overview
6.7.2. Company Snapshot
6.7.3. Operating Business Segments
6.7.4. Product Portfolio
6.7.5. Business Performance
6.7.6. Key Strategic Moves And Developments

6.8. Shanghai Junshi Biosciences Co., Ltd.

6.8.1. Company Overview
6.8.2. Company Snapshot
6.8.3. Operating Business Segments
6.8.4. Product Portfolio
6.8.5. Business Performance
6.8.6. Key Strategic Moves And Developments

6.9. Beigene

6.9.1. Company Overview
6.9.2. Company Snapshot
6.9.3. Operating Business Segments
6.9.4. Product Portfolio
6.9.5. Business Performance
6.9.6. Key Strategic Moves And Developments

6.10. Jiangsu Hengrui Medicine Co., Ltd.

6.10.1. Company Overview
6.10.2. Company Snapshot
6.10.3. Operating Business Segments
6.10.4. Product Portfolio
6.10.5. Key Strategic Moves And Developments

facebooktwittergoogle_plusredditpinterestlinkedinmail